Correlation between platelet/lymphocyte ratio and clinical prognosis of small cell lung cancer

WANG Li-wei; WANG Jian-wei; JIA Wei; QIANG Wei; XUE Mei; MA Chao; WEI Xiu-qin

doi:10.16689/j.cnki.cn11-9349/r.2019.02.008

PDF(879 KB)

Electronic Journal of Metabolism and Nutrition of Cancer ›› 2019, Vol. 6 ›› Issue (2) : 196-199. DOI: 10.16689/j.cnki.cn11-9349/r.2019.02.008

Correlation between platelet/lymphocyte ratio and clinical prognosis of small cell lung cancer

WANG Li-wei， WANG Jian-wei， JIA Wei， QIANG Wei， XUE Mei， MA Chao， WEI Xiu-qin

Author information +

History +

Abstract

Objective To investigate the relationship between platelet to lymphocyte ratio (PLR) and prognosis in patients with small cell lung cancer (SCLC). Methods Clinical data， including platelet and lymphocyte counts， of 165 patients with SCLC admitted to our hospital from June 2008 to June 2018 were collected and retrospectively analyzed and their survival were followed up. The optimal cut-off value of PLR was determined with time-dependent receiver operating curve (ROC curve) analysis in SPSS 22.0 statistical software. The overall survival (OS) and progression-free survival (PFS) of high PLR and low PLR groups were evaluated with Kaplan-Meier analysis respectively and Multivariate Cox regression models were applied to evaluate the independent prognostic significance of PLR. Results ROC curve analysis showed that PLR ＝ 189 was optimal cut-off value. One hundred and twenty cases were found in the low PLR (<189) group and 45 cases fell in the high PLR (≥189) group. The progression-free survival of patients with low PLR was higher than that of high PLR (8.6 months vs 6 months， P=0.016). The overall survival of patients with low PLR was higher than that of high PLR (13.8 months vs 12.1 months， P= 0.016). COX multivariate regression analysis showed that radiotherapy can be used as an independent prognostic factor for both PFS and OS in patients with SCLC(HR=0.488， 95%CI=0.303~0.787， P=0.003； HR=0.314， 95%CI=0.190~0.519， P=0.000. PLR level can be used as an independent prognostic factor for PFS in patients with SCLC (HR=1.538， 95%CI=1.040~2.274， P=0.031)， but not as an independent prognostic factor for OS (HR=1.323， 95%CI=0.883~1.982， P=0.175). Conclusion PLR can reflect the prognosis of patients with SCLC， but it cannot be used as an independent prognostic factor.

Key words

Platelet to lymphocyte ratio / Small cell lung cancer / Prognosis

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

WANG Li-wei， WANG Jian-wei， JIA Wei， QIANG Wei， XUE Mei， MA Chao， WEI Xiu-qin. Correlation between platelet/lymphocyte ratio and clinical prognosis of small cell lung cancer[J]. Electronic Journal of Metabolism and Nutrition of Cancer. 2019, 6(2): 196-199 https://doi.org/10.16689/j.cnki.cn11-9349/r.2019.02.008

References

1.Chan BA， Coward JI．Chemotherapy advances in small-cell lung cancer. J Thorac Dis. 2013；5(suppl 5):s565-s578.
2.Li J， Dai CH， Chen P， et al. Survival and prognostic factors in small cell lung cancer. J Med Oncol. 2010；27(1):73-81.
3.Paesmans M， Sculier JP， Lecomte J， et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. J Cancer. 2000；89(3):523-533.
4.Krug LM，Crapanzano JP， Azzoli CG， et al． Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit proteina phase Ⅱ clinical trial. J Cancer. 2005；103(10):2128-2131．
5.Reck M，Luft A， Szczesna A， et al． Phase Ⅲ randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol.2016；34(31):3740-3748．
6.Ott PA， Elez E， Hiret S，et al．Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study．J Clin Oncol.2017；35(34):3823- 3829．
7.Coussens LM， Werb Z. Inflammation and cancer. J Nature. 2002；420(6917):860-867.
8.Wu G， Yao Y， Bai C， et al．Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patient．J Thorac Cancer.2015；6(3):275-287.
9.Miyamoto R， Inagawa S， Sano N， et al. The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients. J Eur J Surg Oncol.2018；7983(18):30296-30298.
10.Chan JC， Chan DL，Diakos CI， et al.The lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer．J Ann Surg. 2017；265(3):539-546．
11.Coussens LM， Werb Z. Inflammation and cancer. J Nature.2002；420:860-867.
12.Grivennikov SI， Greten FR， Karin M. Immunity， inflammation， and cancer. J Cell. 2010； 140(6):883-899.
13.Bambace NM， Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011；9(2):237-249.
14.Goubran HA， Stakiw J， Radosevic M， et al. Platelet-cancer interactions. J Semin Thromb Hemost. 2014；40(3):296-305.
15.Alexandrakis MG， Passam FH， Moschandrea IA， et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. J Am J Clin Oncol. 2003；26(2):135-140.
16.Xu Z， Xu W， Cheng H， et al. The prognostic role of the platelet-lymphocytes ratio in gastric cancer: a Meta-analysis. J PLoS One. 2016；11(9):e0163719.
17.Krenn-Pilko S， Langsenlehner U， Thurner EM，et al．The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients．J Br J Cancer. 2014；110(10):2524-2530．
18.王鑫，支修益.中性粒细胞/淋巴细胞比值和血小板/淋巴细胞比值对小细胞肺癌患者预后价值的相关研究.中国医学前沿杂志(电子版).2017；5.
19.王琳，吕喜英.外周血中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值对小细胞肺癌患者预后的评估价值.临床肺科杂志.2017；6.
20.Kang MH， Go SI， Song HN， et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. J Br J Cancer. 2014；111(3):452-460.